Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288

被引:9
作者
Agatsuma, T
Abe, K
Furukawa, H
Koga, R
Koizumi, M
Hotoda, H
Kaneko, M
机构
[1] SANKYO CO LTD,ANALYT & METAB RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN
[2] SANKYO CO LTD,NEW LEAD RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN
关键词
oligonucleotide; HIV-1; immunodeficient mouse; SCID;
D O I
10.1016/S0166-3542(97)01032-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We analyzed the anti-HIV-1 activity of an oligonucleotide derivative, R-95288, in severe combined immunodeficient (SCID/beige) mice transplanted with normal human peripheral blood leukocytes (PBLs), designated hu-PBL-SCID/beige mice, The human chimeric mice were inoculated with HIV-1(CC1) 3 weeks after the transplantation and sacrificed 2 weeks later. Virus infection was determined by coculture of splenocytes with fresh human PBLs and also by detection of HIV- specific DNA sequences using the polymerase chain reaction. No evidence of infection was observed in mice treated with R-95288 (100 mg/kg/day) using intraperitoneal delivery by osmotic minipumps starting 1 day before virus challenge. In contrast, virus infection was observed in over 80% of the saline-treated control mice. In addition, partial inhibition of HIV-1 infection was obtained in mice treated subcutaneously with R-95288 (100 mg/kg/day). Toxicity towards the engrafted human cells was not observed by flow cytometric analysis. Moreover, R-95288 failed to inhibit lymphocyte proliferation (CC50 > 400 mu g/ml), while 90% inhibition of HIV-1 replication was achieved at 3.1 mu g/ml in vitro. These results suggest the ability of R-95288 to protect the human chimeric mice against HIV-1 infection. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 25 条
[1]  
AGATSUMA T, UNPUB ANTIVIRAL RES
[2]   MDL 74,968, a new acyclonucleotide analog: Activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection [J].
Bridges, CG ;
Taylor, DL ;
Ahmed, PS ;
Brennan, TM ;
Hornsperger, JM ;
Nave, JF ;
Casara, P ;
Tyms, AS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1072-1077
[3]  
CROY BA, 1990, J REPROD FERTIL, V88, P231, DOI 10.1530/jrf.0.0880231
[4]   MECHANISM OF INHIBITION OF HIV-1 INFECTION IN-VITRO BY GUANINE-RICH OLIGONUCLEOTIDES MODIFIED AT THE 5' TERMINAL BY DIMETHOXYTRITYL RESIDUE [J].
FURUKAWA, H ;
MOMOTA, K ;
AGATSUMA, T ;
YAMAMOTO, I ;
KIMURA, S ;
SHIMADA, K .
NUCLEIC ACIDS RESEARCH, 1994, 22 (25) :5621-5627
[5]  
FURUKAWA H, 1997, IN PRESS ANTISENSE R
[6]   PREEXPOSURE AND POSTEXPOSURE PROTECTION AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION MEDIATED BY A MONOCLONAL-ANTIBODY [J].
GAUDUIN, MC ;
SAFRIT, JT ;
WEIR, R ;
FUNG, MSC ;
KOUP, RA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1203-1209
[7]  
KOGA R, 1996, ANTIVIR RES, V47, pA32
[8]  
KUYK RV, 1994, J IMMUNOL, V153, P4826
[9]   QUANTITATIVE ASSESSMENT OF HIV-1 DNA LOAD BY COAMPLIFICATION OF HIV-1 GAG AND HLA-DQ-ALPHA GENES [J].
LEE, TH ;
SUNZERI, FJ ;
TOBLER, LH ;
WILLIAMS, BG ;
BUSCH, MP .
AIDS, 1991, 5 (06) :683-691
[10]   STEPWISE MECHANISM OF HIV REVERSE-TRANSCRIPTASE - PRIMER FUNCTION OF PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE [J].
MAJUMDAR, C ;
STEIN, CA ;
COHEN, JS ;
BRODER, S ;
WILSON, SH .
BIOCHEMISTRY, 1989, 28 (03) :1340-1346